Stevanato Group Updates 2024 Financial Outlook
Company Announcements

Stevanato Group Updates 2024 Financial Outlook

Stevanato Group (STVN) has released an update.

Stevanato Group S.p.A., a leading provider of pharmaceutical solutions, has reported a marginal revenue increase of 2% in the second quarter of 2024, reaching €259.6 million, with high-value solutions making up 40% of the total revenue. The company has revised its fiscal year 2024 guidance, with expected revenue between €1,090 million to €1,110 million, and adjusted EBITDA anticipated to be €264 million to €272 million. Challenges in the Engineering Segment due to project delays and higher costs have impacted profitability, but the company remains positive about its growth prospects and strong product demand.

For further insights into STVN stock, check out TipRanks’ Stock Analysis page.

Related Articles
TheFlyStevanato Group price target raised to $24 from $23 at UBS
TipRanks Auto-Generated NewsdeskStevanato Group Q3 2024 Earnings Overview
TipRanks Auto-Generated NewsdeskStevanato Group Adjusts Earnings Amidst Q3 Revenue Growth
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App